Please provide your email address to receive an email when new articles are posted on . Any bleeding event regardless of severity can adversely impact a patient. Factor XI and XIa inhibitors in ...

Concomitant use of SSRIs and OACs was associated with a 33% increased risk for major bleeding. Among patients with atrial fibrillation (AF), concomitant use of selective serotonin reuptake inhibitors ...

Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...

Two of three commonly prescribed non-vitamin K oral anticoagulants (NOACs)—dabigatran and apixaban—have similar rates of major bleeding compared with aspirin, a large systematic review and ...

Concomitant use of selective serotonin reuptake inhibitors (SSRIs) and oral anticoagulants (OACs) in patients with atrial fibrillation was tied to an increased risk of major bleeding compared with OAC ...

In the CKD population treated with oral anticoagulants for atrial fibrillation, major bleeding is more likely in male patients and those with congestive heart failure, vascular disease, and a history ...

In patients undergoing revascularization for left main coronary artery disease, CABG is associated with higher rates of all bleeds and in-hospital major bleeding, while PCI is linked to more ...

ORLANDO -- Researchers identified four predictors of clinically relevant bleeding in patients receiving extended anticoagulation with apixaban (Eliquis) for cancer-associated venous thromboembolism ...

Please provide your email address to receive an email when new articles are posted on . Rivaroxaban was linked to higher rates of major bleeding compared with low-dose aspirin. Apixaban and dabigatran ...

Data are presented as median and interquartile range or number and percentage unless indicated otherwise. SI conversion factors: to convert hemoglobin to mmol/l, multiply by 0.1562; NT-proBNP to ...